Consistent with these studies, we found that FGFR1 reverted the anti-glycolytic function of miR-361-5p by upregulating the activity of PDHK1 and LDHA, which enrich the mechanism that miR-361-5p inhibited BC cells glycolysis and proliferation. This evidence concerns the gene FGFR1 and breast cancer.